ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
accruals factor · long-only model fund

Foundry Healthcare Earnings Quality (Accruals) Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FACHHYPOTHETICAL MODEL
Since ’99
+402%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
May 2019
placeholder
Full Sharpe
0.35
Ann. Return (LS)
8.7%
Ann. Volatility
24.6%
Max Drawdown
-58.9%
Test Sharpe ’19–26
-0.01
Test FF5 α (ann.)
-0.8%
vs Fama-French 5
Test FF5 α t-stat
-0.12
not significant
Monthly turnover
19%
of the long leg, per rebalance
Cumulative return (LS)
402%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.63
what this fund holds
Long leg ann. return
16.1%
buyable, long-only
Long-short Sharpe
0.35
requires shorting
Bottom bucket ann. return
7.4%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
12.48%
2DXCM
DEXCOM INCHealthcare$29.58B
9.33%
3MRNA
MODERNA INCHealthcare$24.53B
7.74%
4UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
7.17%
5BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
4.32%
6BMRN
BIOMARIN PHARMACEUTICAL INCHealthcare$11.52B
3.63%
7CYTK
CYTOKINETICS INCHealthcare$9.98B
3.15%
8HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
2.91%
9OSCR
OSCAR HEALTH INCHealthcare$8.77B
2.77%
10PACS
PACS GROUP INCHealthcare$7.30B
2.30%
11MIRM
MIRUM PHARMACEUTICALS INCHealthcare$7.25B
2.29%
12HNGE
HINGE HEALTH INCHealthcare$6.74B
2.13%
13SRRK
SCHOLAR ROCK HOLDING CORPHealthcare$6.33B
2.00%
14TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
1.66%
15DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
1.52%
16VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
1.36%
17ALHC
ALIGNMENT HEALTHCARE INCHealthcare$4.26B
1.34%
18ICUI
ICU MEDICAL INCHealthcare$3.94B
1.24%
19DOCS
DOXIMITY INCHealthcare$3.94B
1.24%
20RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
1.20%
21DNLI
DENALI THERAPEUTICS INCHealthcare$3.70B
1.17%
22RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
1.09%
23RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
0.91%
24SUPN
SUPERNUS PHARMACEUTICALS INCHealthcare$2.79B
0.88%
25CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
0.88%
26VERA
VERA THERAPEUTICS INCHealthcare$2.76B
0.87%
27KOD
KODIAK SCIENCES INCHealthcare$2.67B
0.84%
28ASTH
ASTRANA HEALTH INCHealthcare$2.50B
0.79%
29PGNY
PROGYNY INCHealthcare$2.50B
0.79%
30NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
0.76%
31BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.74%
32AGIO
AGIOS PHARMACEUTICALS INCHealthcare$2.36B
0.74%
33BHVN
BIOHAVEN LTDHealthcare$2.32B
0.73%
34IOVA
IOVANCE BIOTHERAPEUTICS INCHealthcare$2.23B
0.70%
35SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.70%
36AGL
AGILON HEALTH INCHealthcare$2.17B
0.68%
37CDNA
CAREDX INCHealthcare$2.05B
0.65%
38SNDX
SYNDAX PHARMACEUTICALS INCHealthcare$2.02B
0.64%
39AMLX
AMYLYX PHARMACEUTICALS INCHealthcare$1.97B
0.62%
40NVCR
NOVOCURE LTDHealthcare$1.84B
0.58%
41ZYME
ZYMEWORKS INCHealthcare$1.77B
0.56%
42TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.54%
43ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.53%
44FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.53%
45CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
0.53%
46VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.50%
47NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.50%
48INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.49%
49AHCO
ADAPTHEALTH CORPHealthcare$1.49B
0.47%
50INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.46%
51MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.46%
52AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.43%
53ETON
ETON PHARMACEUTICALS INCHealthcare$1.16B
0.37%
54MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.36%
55EYPT
EYEPOINT INCHealthcare$1.12B
0.35%
56PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.32%
57FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.32%
58KURA
KURA ONCOLOGY INCHealthcare$964M
0.30%
59ANNX
ANNEXON INCHealthcare$950M
0.30%
60REPL
REPLIMUNE GROUP INCHealthcare$859M
0.27%
61HSTM
HEALTHSTREAM INCHealthcare$832M
0.26%
62BBNX
BETA BIONICS INCHealthcare$771M
0.24%
63AURA
AURA BIOSCIENCES INCHealthcare$723M
0.23%
64SPRY
ARS PHARMACEUTICALS INCHealthcare$695M
0.22%
65ACHV
ACHIEVE LIFE SCIENCES INCHealthcare$644M
0.20%
66NGNE
NEUROGENE INCHealthcare$590M
0.19%
67WEAV
WEAVE COMMUNICATIONS INCHealthcare$575M
0.18%
68CTEV
CLARITEV CORPHealthcare$518M
0.16%
69ARVN
ARVINAS INCHealthcare$517M
0.16%
70VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.15%
71CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.14%
72ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.13%
73EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.12%
74TBRG
TRUBRIDGE INCHealthcare$394M
0.12%
75UPB
UPSTREAM BIO INCHealthcare$382M
0.12%
76ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.11%
77CV
CAPSOVISION INCHealthcare$335M
0.11%
78VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.10%
79FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.10%
80TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.09%
81MASS
908 DEVICES INCHealthcare$278M
0.09%
82TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.08%
83ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.08%
84GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.08%
85KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.07%
86INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.06%
87RCEL
AVITA MEDICAL INCHealthcare$157M
0.05%
88AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.04%
89JYNT
JOINT CORPHealthcare$127M
0.04%
90RLYB
RALLYBIO CORPHealthcare$87M
0.03%
91PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.02%
92ACET
ADICET BIO INCHealthcare$76M
0.02%
93SCLX
SCILEX HOLDING COHealthcare$72M
0.02%
94EDSA
EDESA BIOTECH INCHealthcare$59M
0.02%
95EXOZ
EXOZYMES INCHealthcare$51M
0.02%

Full long-leg book as of July 2026 · cap-weighted · total market cap $317.00B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
12%3
18%6
36%9
3%6
8%11
7%11
2%14
1%7
2%11

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 85% toward Large, 66% toward Growth. +12% unclassified (17 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt85% → Large
SmallLarge
Value ↔ growth tilt66% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.5 (95% CI 1.0-1.9)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
14.1%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.47x
within
parametric
1.60x
within
cornish fisher
2.66x
over · unreliable

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1996
Entirely since publication
All 331 months of our record post-date the 1996 paper.
Sharpe 0.358.7% p.a.January 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
81%
21 of 26 3-year windows made money
Worst window
-0.38
Sharpe, January 2018 – December 2020
January 1999July 2026
Median Sharpe
0.36
Dispersion
0.43
Best window
1.16

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.66.4%3.2%
3 yearsp.a.17.6%-0.9%
5 yearsp.a.5.5%0.9%
10 yearsp.a.10.6%0.4%
Since inceptionp.a.14.0%6.0%
Calendar years
YearLong legLong-short
20267 mo32.4%21.3%
202523.3%-13.0%
2024-1.3%-8.7%
20233.1%-1.1%
2022-17.8%7.3%
202118.6%26.3%
202010.5%-28.2%
201917.7%-7.1%
20186.8%17.9%
201742.7%11.9%
2016-9.9%6.7%
20157.4%-9.6%
201427.6%4.4%
201352.9%4.5%
201221.1%9.9%
201113.6%5.0%
201019.0%14.2%
200917.9%1.4%
2008-19.6%15.0%
20072.6%-20.9%
200618.8%12.5%
20053.1%-0.3%
2004-9.4%-13.0%
2003101.1%62.9%
2002-38.0%-0.9%
20013.2%42.7%
200065.8%5.5%
199960.6%45.6%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FACH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-05-17 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$317.00B

Methodology

The Foundry Healthcare Earnings Quality (Accruals) Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Earnings Quality (Accruals) signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.